Publications
Our team is dedicated to the continuing study and education of emerging viruses
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
Ralph A. Tripp and David E. Martin
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression
Sanju Sinha †,‡, Kuoyuan Cheng †,‡, Alejandro A Schäffer ‡, Kenneth Aldape ‡, Eyal Schiff & Eytan Ruppin
Probenecid inhibits SARS‑CoV‑2 replication in vivo and in vitro
Jackelyn Murray, Robert J. Hogan, David E. Martin, Kathy Blahunka, Fred D. Sancilio, Rajiv Balyan, Mark Lovern, Richard Still & Ralph A. Tripp
Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy
Olivia Perwitasari, Xiuzhen Yan, Scott Johnson, Caleb White, Paula Brooks, S. Mark Tompkins, Ralph A. Tripp
Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
Jackelyn Murray, Harrison C. Bergeron, Les P. Jones, Zachary Beau Reener, David E. Martin, Fred D. Sancilio and Ralph A. Tripp
The Pathophysiology of COVID-19 and SARS-CoV-2 Infection
Leigh Anne Swayne, Scott R. Johnstone, Chen Seng Ng, Juan C. Sanchez-Arias,
Miranda E. Good, Silvia Penuela, Alexander W. Lohman, Abigail G. Wolpe, Victor E. Laubach, Michael Koval, and Brant E. Isakson
